

APPENDIX 13: DETAILED RESULTS FOR OTHER OUTCOMES

Treatment-Naive

TABLE 183: WITHDRAWALS — ALL-CAUSE(S)

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	N	N	%
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	34	371	9%
		(33) T12 PR24-48 RGT q12	40	369	11%
Dieterich et al., 2014-1	1	(42) SIM12 PR24-48 RGT	4	53	8%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	1	209	0%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	0	100	0%
Fried et al., 2013 PILLAR	1	(1) PR48	6	77	8%
		(42) SIM12 PR24-48 RGT	7	77	9%
Gane et al., 2013-1 ^a ELECTRON	2+3	(3) SOF12 + RBV12	0	4	0%
		(40) SOF12 + PR12	0	4	0%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	0	25	0%
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	25	0%
Jacobson et al., 2014 QUEST-1	1	(1) PR48	10	130	8%
		(42) SIM12 PR24-48 RGT	21	264	8%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	36	361	10%
		(32) T12 PR24-48 RGT q8	35	363	10%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	12	216	6%
		(8) SOF8 + LDV8	13	215	6%
		(9) SOF8 + LDV8 + RBV8	16	216	7%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	4	52	8%
Lalezari et al. et al., 2015	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	1	38	3%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	1	19	5%
		(8) SOF8 + LDV8	0	20	0%
		(9) SOF8 + LDV8 + RBV8	0	21	0%
Lawitz et al., 2013-1 PROTON	1	(1) PR48	12	26	46%
		(41) SOF12 PR24-48 RGT	5	47	11%
Lawitz et al., 2013-2 PROTON	2+3	(40) SOF12 + PR12	1	25	4%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	36	327	11%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	39	256	15%
		(70) PR24	88	243	36%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	N	N	%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	1	205	0%
Manns et al., 2014 QUEST-2	1	(1) PR48	17	134	13%
		(42) SIM12 PR24-48 RGT	12	257	5%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	6	82	7%
		(33) T12 PR24-48 RGT q12	6	79	8%
Mizokami et al. et al., 2015	1	(6) SOF12 + LDV12	0	83	0%
		(10) SOF12 + LDV12 + RBV12	2	83	2%
Molina et al., 2015-1 PHOTON-2	1	(4) SOF24 + RBV24	2	112	2%
Molina et al., 2015-2 PHOTON-2	2	(3) SOF12 + RBV12	0	19	0%
Molina et al., 2015-3 PHOTON-2	3	(4) SOF24 + RBV24	2	57	4%
Molina et al., 2015-4 PHOTON-2	4	(4) SOF24 + RBV24	0	31	0%
Omata et al., 2014	2	(3) SOF12 + RBV12	0	90	0%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	1	10	10%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	1	25	4%
		(71) SOF24 + RBV (low dose) 24	3	25	12%
Osinusi et al., 2015	1	(6) SOF12 + LDV12	1	50	2%
Poordad et al., 2011 SPRINT2	1	(1) PR48	128	363	35%
		(46) B24 PR28-48 RGT	78	368	21%
Rodriguez-Torres et al., 2015	1+2+3+4	(40) SOF12 + PR12	4	23	17%
Sulkowski et al., 2014	1+2+3	(3) SOF12 + RBV12	5	26	19%
		(4) SOF24 + RBV24	28	115	24%
Sulkowski et al., 2013-1	1	(1) PR48	2	7	29%
		(39) T12 PR48 q8	1	7	14%
Sulkowski et al., 2013-2	1	(1) PR48	1	8	13%
		(39) T12 PR48 q8	3	15	20%
Sulkowski et al., 2013	1	(1) PR48	7	34	21%
		(50) B44 PR48	8	64	13%
Zeuzem et al., 2015 C-EDGE	1+4+6	(22) GRZ12 + ELB12	3	316	1%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Only the number of withdrawals from genotype 2 participants is reported.